Stanford researchers have developed a new therapeutic approach to protect neurons and promote axon regeneration by restoring mitochondrial transport within axons, a key process disrupted in many neurodegenerative diseases.
Stanford scientists have developed Plate-C, a high-throughput screening platform that captures genome-wide 3D chromatin architecture as a comprehensive cellular phenotype.
High-grade gliomas, including glioblastoma and diffuse midline glioma are the most common malignant brain tumor types and leading causes of brain-tumor-related death in adults and children, respectively.
Stanford researchers have repurposed two existing drugs and created a combined nanoparticle formulation that provides both intraocular pressure management and neuroprotection for glaucoma therapy.
Stanford researchers have developed a novel therapeutic approach for neurodegenerative diseases by targeting endoplasmic reticulum (ER) stress in neurons using CHOP inhibitors, with significant potential for development into first-in-class neuroprotective drugs for neurodegene
Stanford scientists have developed an innovative 3D brain organoid culture system derived from adult neural stem cells to model neurodegenerative diseases like Alzheimer's and enable high-throughput drug screening.
Stanford scientists have developed a high throughput screening method to identify therapeutics known as translational activators to treat protein synthesis disorders and ribosomopathies.
Researchers at Stanford University have discovered a first-in-class covalent inhibitor that binds to activated Fis1 and prevents mitochondrial fission and dysfunction.
The blood-brain barrier is a huge challenge when it comes to the delivery of therapeutic proteins to treat genetic diseases, injury, and neurodegenerative diseases.
Researchers at Stanford have found that nascent polypeptide-associated complex (NAC) and the apical domain of CCT1, as well as peptide fragments and fusion proteins containing them, can be used to suppress pathological protein aggregation.